Compare APA & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APA | HALO |
|---|---|---|
| Founded | 1954 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 14.8B |
| IPO Year | 2021 | 2001 |
| Metric | APA | HALO |
|---|---|---|
| Price | $47.48 | $97.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 28 | 9 |
| Target Price | $50.31 | ★ $119.89 |
| AVG Volume (30 Days) | ★ 5.5M | 2.1M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | ★ 75.77 | N/A |
| EPS | ★ 5.36 | 5.12 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $15.78 | $35.97 |
| Revenue Next Year | N/A | $14.85 |
| P/E Ratio | ★ $9.03 | $19.65 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.06 | $61.23 |
| 52 Week High | $52.96 | $134.00 |
| Indicator | APA | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 24.66 |
| Support Level | $34.03 | $64.08 |
| Resistance Level | $52.96 | $111.15 |
| Average True Range (ATR) | 1.84 | 4.73 |
| MACD | -0.22 | -3.52 |
| Stochastic Oscillator | 46.28 | 0.82 |
APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.